Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Recruiting Phase 2 Interventional Study
Chemotherapy, Adjuvant Lung Adenocarcinoma, Stage I Treatment Histological Type of Neoplasm
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 – 70
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
460 (estimated)
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Completely resected Stage I NSCLC as defined by the International Staging System * Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma * Patients must be randomized within 4 weeks from the date of surgery * No prior chemotherapy or radiation for non…
Contacts

Yingran Shen, PhD

86-18117166317

elaineshen91@gmail.com

CONTACT